Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lantheus-holding ...

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR LANTHEUS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUIN ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Far ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 24, 2025 /PRNewswire/ -- Robbins LLPÂ reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products. The Company's key Radiopharmaceutical Oncology product is Pylarify, a PET i ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important November 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Lantheus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Lantheus and certain ...

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. According to the complaint, defendants provided investors with misleading statements concerning the true state of Pylarify's competitive position; notably, that Lantheus was not equipp ...

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”), have until Monday, November 10, 2025 to seek appointment as lead plaintiff of the Lantheus class action lawsuit. Captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.), the Lantheus class action lawsuit charges Lantheus and certain of Lantheus’ ...

合作协议核心内容 - Lantheus与GE HealthCare宣布就piflufolastat F18在日本市场达成独家许可协议，GE HealthCare将负责该产品在日本的开发、生产和商业化[1] - 协议涵盖前列腺癌诊断及伴随诊断用途，该产品在美国市场名为PYLARIFY，是一种用于前列腺癌患者PSMA阳性病灶正电子发射断层扫描成像的放射性药物[1] - 协议内容包括监管档案转移、生产技术转让和技术支持，以推动GE HealthCare在日本进行临床开发，并寻求监管批准和商业发布[2] - GE HealthCare将利用其在2025年3月收购的日本领先放射性药物公司Nihon Medi-Physics Co, Ltd后获得的广泛生产网络和研发专长[2] - 根据协议，GE HealthCare将向Lantheus支付首付款、开发里程碑付款以及基于日本产品销售额的分级特许权使用费，双方将成立联合指导委员会监督开发和商业化活动[3] 市场机会与战略意义 - 前列腺癌是全球第四大常见癌症，日本在2022年成为全球前列腺癌病例数第三高的国家，仅次于美国和中国[3] - 此次合作有望显著扩展Lantheus诊断成像剂在关键国际市场的影响力，利用GE HealthCare和NMP的深厚区域专长来推进前列腺癌的检测和护理[3] - 对于GE HealthCare，此次合作是其扩展放射性药物管线、履行改善患者获得创新诊断技术承诺的战略进展，使其获得一款已在欧美获批的同类最佳PET成像剂[3] - 将靶向PET成像剂引入新地区符合Lantheus“发现、对抗和追踪疾病以改善患者预后”的企业宗旨，有助于为日本前列腺癌检测、诊断和监测建立更个性化的方法基础[3] 产品背景与市场地位 - Piflufolastat F18于2021年获美国FDA批准，在美国市场名为PYLARIFY，是美国使用量第一的PSMA PET成像剂[4] - 该产品拥有丰富的真实世界使用经验，已在美国48个州完成超过50万次扫描[4] - 2023年，该产品在欧盟获批，市场名为PYLCLARI，其欧洲权利已由Lantheus旗下公司Progenics Pharmaceuticals授权给Curium[4] - PYLARIFY是一种氟化小分子PSMA靶向PET成像剂，可用于可视化淋巴结、骨和软组织转移，以确定复发性或转移性前列腺癌的存在[5] - 该产品将PET成像的准确性、PSMA靶向的精确性和F18放射性同位素的清晰度相结合，推荐剂量为333 MBq（9 mCi），可接受范围为296 MBq至370 MBq（8 mCi至10 mCi）[5] 公司背景 - Lantheus是一家领先的专注于放射性药物的公司，总部位于马萨诸塞州，在美国新泽西、加拿大、德国、瑞典和瑞士设有办事处，提供放射性药物解决方案已有近70年历史[19] - GE HealthCare是一家全球领先的医疗保健解决方案提供商，业务涵盖医疗技术、药物诊断以及集成化、云优先的AI赋能解决方案、服务和数据分析，是一家197亿美元的业务，拥有约53,000名员工[20]